Clearity’s Scientific Director, Dr. Deb Zajchowski, presented a poster at the SGO’s 50th Annual Meeting on Women’s Cancers entitled: Genomic Mutation Profiles of Paired Ovarian Cancers Across Time.
The data presented describes some of the research being done utilizing The … Read more
Since tumors often have unique defects in the DNA damage response (DDR) pathway, identifying the molecular mechanisms that underlie how cells repair various DNA lesions is critical to selecting the appropriate clinical treatments. Inhibitors to poly-(ADP-ribose) polymerase (PARP) are examples … Read more
By Will Pass
Women who have survived epithelial ovarian cancer (EOC) more often report severe long-term fatigue than healthy women, according to a case-control study involving more than 600 individuals.
Ovarian cancer survivors had a higher rate of sleep disturbance, … Read more
Ovarian cancer is not the most common form of cancer, but it’s among the deadliest. That’s because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Women’s Research Institute … Read more
Clearity’s Executive Director, Hillary Theakston, spoke on a panel of industry leaders at SXSW on ‘Frontiers of Cancer: Racing Toward A Cure’. Hillary, along with fellow panelists Amy Puliafito, Bobbie Rimel, MD, and Karl Handelsman discussed major investments, … Read more
By Susan Moench
The results from the Lymphadenectomy in Ovarian Neoplasms (LION) trial, published in the New England Journal of Medicine, which compared systematic pelvic and paraaortic lymphadenectomy with no lymphadenectomy in some women with advanced ovarian cancer, showed … Read more
By Krista Conger
Over the years, I’ve written quite a bit about a protein called CD47 that is found on the surface of many types of cancer cells, as well as on aging red blood cells.
In 2009, researchers in … Read more
By Jane Biehl, PhD
Recovering from cancer and its aftermath is like grief; always changing, undulating and rippling like a tide.
Like many people, I was very naïve about how much cancer would change my life. I thought that one … Read more
US-based biotechnology company ImmunoGen has reported negative top-line results from the Phase III FORWARD I ovarian cancer trial of mirvetuximab soravtansine.
The study failed to meet its primary endpoint of progression-free survival (PFS). Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) … Read more
By Maria Cohut
Some types of cancer, such as ovarian cancer, tend to remain undetected until they are too advanced for treatment to be effective. Now, an innovative tool may be able to detect cancer easily, quickly, and in minuscule … Read more
By Dave Levitan
Conservative management of adnexal masses classified as benign was associated with a low risk of subsequent malignant ovarian cancer, according to a new study.
“Adnexal masses are often detected incidentally and most of them prove to be … Read more
By Milton Packer, MD
Most observers do not understand what the academic leaders of a clinical trial really do. To many, the steering committee simply takes its marching orders from industry sponsors. Some believe that every trial is designed by … Read more
Most women dread turning 40, not me. The morning of February 9th, 2017, I hopped out of bed and headed off to teach my weekly cycling class. Health and fitness are two of my passions. I’ve been a group fitness … Read more
A brand new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
In patients with advanced, drug-resistant cancers, over a quarter with cervical and … Read more
By Michael Murray
There are diseases and health conditions that are essentially invisible to us until it is too late.
When those problems are life-threatening, such as cancer, and if there is a period when something could be done, then … Read more
A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy … Read more
Xconomy San Diego — Last week, it was reported by multiple media outlets (see here, and here, and here) that a group of Israeli scientists had found “a cure for all cancer” and that … Read more
Women may not need to undergo surgery for non-cancerous ovarian cysts, avoiding potential surgical complications.
This is the finding of new research, by a team of international scientists from institutions including Imperial College London and KU Leuven, published in The … Read more
Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare … Read more
